Purpose: Vascular insufficiency in peripheral arterial disease (PAD) reduces limb-blood flow and results in tissue ischemia. In response, circulating monocytes produce vascular endothelial growth factor (VEGF-A). Patients with PAD and mouse models of metabolic ischemic disease have increased Wingless-Type MMTV Integration Site Family 5a (Wnt5a) activity and decreased Wnt5a modulator SFRP5. This has been shown to increase the anti-angiogenic VEGF isoform in circulating monocytes from both humans and mice. VEGF splicing has previously been shown to be regulated by phosphorylation of splicing factor SRSF1 by the kinase, SRPK1. To determine whether this was the case in monocytes in mice with ischemia, we investigated the effect of SRPK1 inhibition with SPHINX31 on revascularisation after ischemia in mice with Wnt5A overexpression in monocytes. Methods: All animal procedures met the requirements dictated by the Animals (Scientific Procedures) Act 1986/ASPA. 21 transgenic mice (C57/BlJ, 10-12 weeks, both genders) were used. Wildtype (WT) littermates and Wnt5a gain of function (LysM-Wnt5aGOF) were subjected to left femoral artery ligation under anaesthesia with 2% isoflurane. Moor FLPI-2 laser perfusion speckle camera was performed on day 0 (pre- and post-surgery), 3, 7, 14 and 21 to measure the blood flow. LysM-Wnt5aGOF received SPHINX31 (0.8mg/kg, i.p.) biweekly. After 21 days, mice were euthanised and the whole body was fixed perfused with 4% paraformaldehyde/ phosphate buffered saline (PFA/PBS) under terminal anaesthesia (meditomadine 1mg/kg, ketamine 75mg/kg i.p). The gastrocnemius muscle was collected, cryosectioned (5μM) and stained for blood vessels with Isolectin B4 (IB4) and arterioles with smooth muscle actin antibody (aSMA). Results: The blood flow recovery in LysM-Wnt5aGOF (day 3 19 ± 2.56%, day 7 40 ± 3%) was significantly slower than WT mice (day 3 70 ± 4%, day 7 80 ± 3%). This impaired revascularisation was rescued by SPHINX31 treatment on day 3 (57 ± 14%) and day 7 (62 ± 11%) post-surgery (N=7, p<0.0001, two-way ANOVA). Staining of the muscles from these mice for arterioles indicated that impaired recovery of LysM-Wnt5aGOF was due to reduced arteriogenesis. Conclusion: Monocytes overexpressing Wnt5a in PAD models result in impaired collateralisation, insufficient angiogenesis and poor arteriogenesis. This was reversed, not enhanced, by SPHINX31 suggesting that the impaired revascularisation in PAD could be SRPK1 dependant and could be used as a potential therapeutic.